US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
01/12/22 - 18:30
2023 Annual Calendar of Corporate Events (288 KB)
Other
09/11/22 - 7:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products
Molecular
07/11/22 - 7:12
DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products
Molecular
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
05/10/22 - 6:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products
Molecular
14/09/22 - 0:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products
Molecular
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
14/07/22 - 20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products
Immunodiagnostic
07/06/22 - 18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
20/05/22 - 7:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products
Molecular
09/05/22 - 7:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
06/05/22 - 17:33
Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
02/05/22 - 12:55
Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
29/04/22 - 16:26
Shareholders' meeting 2022 (166.12 KB)
Other
22/04/22 - 12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
13/04/22 - 16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
08/04/22 - 19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
08/04/22 - 9:53
Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
05/04/22 - 9:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
04/04/22 - 18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
16/03/22 - 17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
08/03/22 - 7:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products
Molecular
13/01/22 - 7:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products
Molecular